The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
DASL-HiCaP: A randomized, phase 3, double-blind trial of darolutamide with androgen-deprivation therapy and definitive or salvage radiation for localized very high-risk prostate cancer.
 
Tamim Niazi
Stock and Other Ownership Interests - Knight Pharmaceuticals
Honoraria - Abbvie; Astellas Pharma; Bayer; Janssen Oncology; Merck; Sanofi; Tersera; Tolmar
Consulting or Advisory Role - Abbvie; AstraZeneca Canada; Bayer; Janssen Oncology; Sanofi; Tersera
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst); Tersera (Inst)
Travel, Accommodations, Expenses - Janssen Oncology; Sanofi; Tersera
 
Sean Matthew McBride
Consulting or Advisory Role - AstraZeneca; Janssen
Research Funding - AstraZeneca; Genentech
 
Scott Williams
Consulting or Advisory Role - Amgen; Janssen (Inst)
Travel, Accommodations, Expenses - Astellas Pharma
 
Ian D. Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Medivation (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
 
Martin R. Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Tilray (Inst)
Travel, Accommodations, Expenses - Medivation/Pfizer
 
Andrew James Martin
No Relationships to Disclose
 
Hans T. Chung
No Relationships to Disclose
 
Felicia Roncolato
No Relationships to Disclose
 
Annie Ebacher
No Relationships to Disclose
 
Eric Khoo
No Relationships to Disclose
 
Jarad Martin
Employment - GenesisCare; SeeTreat
Stock and Other Ownership Interests - GenesisCare; Margin-Clear
Honoraria - Abbvie
Consulting or Advisory Role - Ferring; Janssen Oncology; Sanofi
Research Funding - Ipsen (Inst); Mundipharma; Varian Medical Systems
 
Tee Sin Lim
No Relationships to Disclose
 
Simon Hughes
Honoraria - Astellas Pharma; Bayer
Consulting or Advisory Role - AstraZeneca; Bayer
Travel, Accommodations, Expenses - Janssen
(OPTIONAL) Uncompensated Relationships - Accord Healthcare (Inst); Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst)
 
David Pryor
Speakers' Bureau - Bayer
 
James W.F. Catto
Honoraria - Abbott Laboratories
Consulting or Advisory Role - AstraZeneca/MedImmune; Ferring; Janssen; Roche
Speakers' Bureau - ASCO; AstraZeneca/MedImmune; MSD Oncology; Nucleix; Roche
Research Funding - Roche/Genentech
Travel, Accommodations, Expenses - European Association of Urology
 
Paul Kelly
Consulting or Advisory Role - Boston Scientific
Travel, Accommodations, Expenses - Boston Scientific
 
Leily Gholam Rezaei
No Relationships to Disclose
 
Scott C. Morgan
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; Tersera
 
Ricardo A. Rendon
Stock and Other Ownership Interests - Myovant Sciences
Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi
Speakers' Bureau - Astellas Pharma; Bayer; Janssen
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; POINT Biopharma; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination